RxDoctor Payments Data

Julian Sprague, MD

Hematology · Burlington, VTNPI 1427260652

Payments from drug & device makers

$53,854in general payments, 2019–2025

Across 50 payments — averaging $1077.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacyclics LLC, An Abbvie Company$48K
  • AbbVie$6K
  • Seagen Inc.$12
  • Pfizer$11

What the payments were for

  • Education$23100%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmacyclics LLC, An Abbvie Company43$48,301
AbbVie5$5,530
Seagen Inc.1$12
Pfizer1$11

How this compares

Too few hematology providers in Vermontto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$81,632
Medicare patients
353
Services billed
776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide37$830,741
CalquenceAcalabrutinib Maleate45$686,265
ImbruvicaIbrutinib41$510,703
BrukinsaZanubrutinib37$500,318
JakafiRuxolitinib Phosphate15$369,277
PromactaEltrombopag Olamine17$346,303
RevlimidLenalidomide19$269,008
Lenalidomide18$257,604
NinlaroIxazomib Citrate20$256,269
JaypircaPirtobrutinib17$235,627
VenclextaVenetoclax20$225,803
SprycelDasatinib23$197,593
Imatinib Mesylate27$76,669
EliquisApixaban82$47,345
NeupogenFilgrastim51$16,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$48,301$510,70341 claims
AbbVieVenclexta$5,530$225,80320 claims
PfizerEliquis$11$47,34582 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Vermonton file to place this against a meaningful peer group, so we don't.

Other hematology in Burlington

Where these figures come from

Is this you, or does something look wrong? →